Compile Data Set for Download or QSAR
Report error Found 143 Enz. Inhib. hit(s) with all data for entry = 1442
TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323219(N-[(R)-2-[3-(2,4-difluorophenyl)-3-pentylazetidin-...)
Affinity DataEC50:  15nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323261(N-[(R)-2-(3-Cyclobutylmethoxy-3-o-tolylazetidin-1-...)
Affinity DataEC50:  15nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323262(N-[(R)-1-(4-Methoxybenzyl)-2-[3-(3-methylbut-2-eny...)
Affinity DataEC50:  15nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323173(N-[(S)-1-[(S)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-...)
Affinity DataEC50:  30nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323258(N-[(R)-2-(3-But-2-ynyloxy-3-o-tolylazetidin-1-yl)-...)
Affinity DataEC50:  30nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323213(N-[(R)-2-[3-(2-fluorophenyl)-3-pentylazetidin-1-yl...)
Affinity DataEC50:  30nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323212(N-{(R)-1-(4-methoxybenzyl)-2-[3-(2-methoxyphenyl)-...)
Affinity DataEC50:  30nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323214(N-[(R)-2-[3-(2-chlorophenyl)-3-pentylazetidin-1-yl...)
Affinity DataEC50:  30nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323172(US9630949, 1 | US9630949, 3 | N-[(S)-1-[(S)-2-(3-B...)
Affinity DataEC50:  60nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323257(N-[(R)-2-(3-But-2-ynyl-3-o-tolylazetidin-1-yl)-1-(...)
Affinity DataEC50:  60nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323194(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Affinity DataEC50:  60nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323239(N-[(R)-2-[3-Butoxy-3-(2-fluorophenyl)azetidin-1-yl...)
Affinity DataEC50:  60nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323212(N-{(R)-1-(4-methoxybenzyl)-2-[3-(2-methoxyphenyl)-...)
Affinity DataEC50:  60nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323253((S)-N-[(R)-2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(...)
Affinity DataEC50:  60nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323236(N-[2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(2,4-dich...)
Affinity DataEC50:  100nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323230(N-[(R)-2-[3-(2,5-difluorophenyl)-3-pentylazetidin-...)
Affinity DataEC50:  100nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323232(N-[(R)-2-[3-(2,6-difluorophenyl)-3-pentylazetidin-...)
Affinity DataEC50:  100nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323225(N-[(R)-2-[3-(3-fluorophenyl)-3-pentylazetidin-1-yl...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323180(N-[(S)-1-[(S)-2-[3-butoxy-3-(3-fluorophenyl)azetid...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323190(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(2,4-d...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323191(N-[(R)-2-(3-cyclopropylmethoxy-3-o-tolylazetidin-1...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323193(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-propoxy-3-o-...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323211(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323230(N-[(R)-2-[3-(2,5-difluorophenyl)-3-pentylazetidin-...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323259(N-[(R)-2-(3-Cyclohexylmethoxy-3-o-tolylazetidin-1-...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323232(N-[(R)-2-[3-(2,6-difluorophenyl)-3-pentylazetidin-...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323260(3-(1H-Imidazol-4-yl)-N-[(R)-1-(4-methoxybenzyl)-2-...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323186(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323179(N-[(S)-1-[(S)-2-[3-butoxy-3-(4-fluorophenyl)azetid...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323224(N-[(R)-2-[3-(3,4-dichlorophenyl)-3-pentylazetidin-...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323207(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-o-t...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323256(N-[(R)-2-(3-Butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323237(N-[(R)-2-(3-cyclohexyl-3-pentylazetidin-1-yl)-1-(4...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323208(N-[(R)-2-[3-(4-fluorophenyl)-3-pentylazetidin-1-yl...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323237(N-[(R)-2-(3-cyclohexyl-3-pentylazetidin-1-yl)-1-(4...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323175(N-[(S)-1-[(S)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323195(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyloxy-3-...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323222(N-[(R)-1-(3,4-dichlorobenzyl)-2-oxo-2-(3-pentyl-3-...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323188(N-[(R)-2-(3-ethoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323198(N-[(R)-2-(3-butyl-3-phenylazetidin-1-yl)-1-(4-meth...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323234(N-[2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-methox...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323217(N-[(R)-1-benzyl-2-oxo-2-(3-pentyl-3-phenylazetidin...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323235(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-phe...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323238(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323201(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323218(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323238(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323210(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323228(N-[(R)-1-(2,4-dichlorobenzyl)-2-oxo-2-(3-pentyl-3-...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323178(N-[(S)-1-[(S)-2-(3-cyclohexyl-3-hydroxyazetidin-1-...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

Displayed 1 to 50 (of 143 total ) | Next | Last >>
Jump to: